Kyiv Darnytsia District Court closed the case against the activist of CF “Patients of Ukraine” Dmytro Sherembey.
The pharmacists accused the activist and two media journalists of allegedly disclosure of trade secret of one of the hepatitis C drugs producer (claimant: LLC “Valartin Pharma”, article 277 of Civil Code “On protection of honor, dignity and business reputation”).
“It is our first victory and as we can see the Court was fair and unbiased, – says Dmytro Sherembey, – we will continue to defend the interests of patients that are violated by dishonest pharmacists such as “Valanin Pharma”.
The core of the matter is that after learning that the company “Valartin Pharma” wants to sell to the state a drug that has not passed clinical trials, Dmytro has unveiled this information as the one that can cause harm to the thousands of Ukrainian patients.
“Instead of conducting clinical trials and proving the safety of the drug the pharmacists have started litigation against patients. This is an extremely inefficient method that may influence the company’s sales. We have proof that some distributors have returned the drug “Alphapeg” to the manufacturer that has not passed clinical trials”, – says Dmytro Sherembey.
Additional information for media:
Natalya Krasnenkova, 067 465 54 26
Charitable Foundation “Patients of Ukraine” (https://patients.org.ua/en/) — organization which mission is to ensure effective treatment for all patients in Ukraine by bringing together the activists in order to influence state laws and policies. We want to see the county where the patients have access to all the drugs they need by implementing an effective medicine where the patient activists are treated with respect, have access to the public information, have the skills of strategic work and cooperate with the state that functions transparently, responsibly and openly. Thus CF “Patients of Ukraine” is recognized by the state agencies, national and international pharmaceutical organizations that are present in Ukraine, clinicians’ communities, patient groups and other players as a legitimate partner.